COVID-19 Collection

Journal article

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Abstract:: Background
The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro, and observational and clinical trial evidence suggesting they prevented progression to severe disease. However, these SSRIs have not been recommended in therapeutic guidelines and their antiviral activity in vivo has not been characterised.

Methods<... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Jittamala, P., Boyd, S., Schilling, W. H. K., Watson, J. A., Ngamprasertchai, T., Siripoon, T., Luvira, V., Batty, E. M., Wongnak, P., Esper, L. M., Almeida, P. J., Cruz, C., Ascencao, F. R., Aguiar, R. S., Ghanchi, N. K., Callery, J. J., Singh, S., Kruabkontho, V., Ngernseng, T., … White, N. J. (2025). Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV). EClinicalMedicine, 80.

MLA Style

Jittamala, P, et al. “Antiviral Efficacy of Fluoxetine in Early Symptomatic COVID-19: an Open-Label, Randomised, Controlled, Adaptive Platform Trial (PLATCOV).” EClinicalMedicine, vol. 80, 2025.

Chicago Style

Jittamala, P, S Boyd, WHK Schilling, et al. 2025. “Antiviral Efficacy of Fluoxetine in Early Symptomatic COVID-19: an Open-Label, Randomised, Controlled, Adaptive Platform Trial (PLATCOV).” EClinicalMedicine 80.
Print

Access Document

Files:: Jittamala_et_al_2025_Antiviral_efficacy_of.pdf

(Preview, Version of record, pdf, 1.1MB, Terms of use)

Publisher copy:: 10.1016/j.eclinm.2024.103036

Authors

+ Jittamala, P More by this author

Role:: Author

+ Boyd, S More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Tropical Medicine
Role:: Author

+ Schilling, WHK More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Tropical Medicine
Role:: Author

+ Watson, JA More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Tropical Medicine
Role:: Author
ORCID:: 0000-0001-5524-0325

+ Ngamprasertchai, T More by this author

Role:: Author

More authors...

Contributors

+ PLATCOV Collaborative Group

Role:: Contributor

+ Wellcome Trust More from this funder

Funder identifier:: https://ror.org/029chgv08
Grant:: 223195/Z/21/Z

Publisher:: Elsevier
Journal:: EClinicalMedicine More from this journal
Volume:: 80
Article number:: 103036
Place of publication:: England
Publication date:: 2025-01-18
Acceptance date:: 2024-12-16
DOI:: 10.1016/j.eclinm.2024.103036
EISSN:: 2589-5370
ISSN:: 2589-5370
Pmid:: 39896880

Language:: English
Keywords:: SARS-CoV-2

antivirals

COVID-19

viral clearance
Pubs id:: 2080476
Local pid:: pubs:2080476
Deposit date:: 2025-02-11
ARK identifier:: ark:/29072/ora_3bb4da37bffd4a21b01891cf01e9f6db

Terms of use

Copyright holder:: Jittamala et al.
Copyright date:: 2025
Rights statement:: © 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP